What is a stock summary page? Click here for an overview.
Business Description
Genscript Biotech Corp
NAICS : 541714
SIC : 8731
ISIN : KYG3825B1059
Share Class Description:
HKSE:01548: Class HCompare
Compare
Traded in other countries / regions
01548.Hong KongG51.GermanyGNNSF.USA Index Membership
Hong Kong Stock ConnectiShares MSCI ACWI Ex US Index Fund IPO Date
2015-12-30Description
Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.64 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -1.99 | |||||
| Interest Coverage | 2.72 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.69 | |||||
| Beneish M-Score | 2.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.1 | |||||
| 3-Year EBITDA Growth Rate | 44.7 | |||||
| 3-Year EPS without NRI Growth Rate | 21.1 | |||||
| 3-Year FCF Growth Rate | 37.3 | |||||
| 3-Year Book Growth Rate | 59.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 12.63 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.7 | |||||
| 9-Day RSI | 49.82 | |||||
| 14-Day RSI | 46.79 | |||||
| 3-1 Month Momentum % | 14.99 | |||||
| 6-1 Month Momentum % | -4.27 | |||||
| 12-1 Month Momentum % | 12.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.72 | |||||
| Quick Ratio | 2.62 | |||||
| Cash Ratio | 2.02 | |||||
| Days Inventory | 51.06 | |||||
| Days Sales Outstanding | 91.24 | |||||
| Days Payable | 48.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 2.51 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.81 | |||||
| Operating Margin % | 3.69 | |||||
| Net Margin % | 495.88 | |||||
| FCF Margin % | -12.12 | |||||
| ROE % | 128.01 | |||||
| ROA % | 73.85 | |||||
| ROIC % | 0.9 | |||||
| 3-Year ROIIC % | 10.5 | |||||
| ROC (Joel Greenblatt) % | -22.37 | |||||
| ROCE % | -4.59 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 1.05 | |||||
| Forward PE Ratio | 14.14 | |||||
| Shiller PE Ratio | 15.41 | |||||
| Price-to-Owner-Earnings | 1.02 | |||||
| PS Ratio | 5.06 | |||||
| PB Ratio | 0.71 | |||||
| Price-to-Tangible-Book | 0.71 | |||||
| Price-to-Operating-Cash-Flow | 39.5 | |||||
| EV-to-EBIT | -16.12 | |||||
| EV-to-Forward-EBIT | -13.59 | |||||
| EV-to-EBITDA | -30.75 | |||||
| EV-to-Forward-EBITDA | -16.85 | |||||
| EV-to-Revenue | 4.42 | |||||
| EV-to-Forward-Revenue | 5.44 | |||||
| EV-to-FCF | -36.46 | |||||
| Price-to-GF-Value | 0.54 | |||||
| Price-to-Projected-FCF | 3.13 | |||||
| Earnings Yield (Greenblatt) % | -6.2 | |||||
| FCF Yield % | -2.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genscript Biotech Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 4,641.724 | ||
| EPS (TTM) (HK$) | 10.566 | ||
| Beta | 0.69 | ||
| 3-Year Sharpe Ratio | -0.14 | ||
| 3-Year Sortino Ratio | -0.21 | ||
| Volatility % | 69.99 | ||
| 14-Day RSI | 46.79 | ||
| 14-Day ATR (HK$) | 0.587098 | ||
| 20-Day SMA (HK$) | 11.168 | ||
| 12-1 Month Momentum % | 12.64 | ||
| 52-Week Range (HK$) | 7.43 - 15.08 | ||
| Shares Outstanding (Mil) | 2,169.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genscript Biotech Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genscript Biotech Corp Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genscript Biotech Corp Frequently Asked Questions
What is Genscript Biotech Corp(HKSE:01548)'s stock price today?
The current price of HKSE:01548 is HK$11.06. The 52 week high of HKSE:01548 is HK$15.08 and 52 week low is HK$7.43.
When is next earnings date of Genscript Biotech Corp(HKSE:01548)?
The next earnings date of Genscript Biotech Corp(HKSE:01548) is 2025-05-13 Est..
Does Genscript Biotech Corp(HKSE:01548) pay dividends? If so, how much?
Genscript Biotech Corp(HKSE:01548) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers